Darolutamide (ODM-201) for the treatment of prostate cancer

  title={Darolutamide (ODM-201) for the treatment of prostate cancer},
  author={Neal D. Shore},
  journal={Expert Opinion on Pharmacotherapy},
  pages={945 - 952}
  • N. Shore
  • Published 24 May 2017
  • Medicine, Biology
  • Expert Opinion on Pharmacotherapy
ABSTRACT Introduction: Androgen deprivation therapy (ADT) is a mainstay initial treatment for advanced hormone-sensitive prostate cancer (HSPC), but disease progression to castration-resistant prostate cancer (CRPC) invariably occurs when patients do not succumb to another disease or comorbidity. Recognition that the androgen receptor (AR) axis continues to drive disease progression has led to the development of several AR-directed approved agents, including abiraterone acetate and enzalutamide… 
Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer
Apalutamide is an oral, investigational, AR antagonist that targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets and may offer potential advantages over the second-generation antiandrogens.
An up-to-date evaluation of darolutamide for the treatment of prostate cancer
Darolutamide is considered to have the lowest probability for adverse events (AEs) compared to apalutamide and enzalUTamide, and this is the main reason that makes darlutamide exceptional in terms of safety and efficacy compared to other drugs in this category.
Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies
The recent Phase III trials SPARTAN and PROPSER demonstrate effective treatment options for the M0CRPC disease state that has historically lacked treatment from high level evidence, and an FDA-approved treatment, Apalutamide, can finally be offered.
Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
This review focuses on resistance mechanisms to enzalutamide, exploring how to overcome them through novel therapeutic options.
Recent Advances in Prostate Cancer Treatment and Drug Discovery
The identification of improved, personalized treatments will be much supported by the major progress recently made in the molecular characterization of early- and late-stage prostate cancer using “omics” technologies, and should greatly help in the choice of novel targeted therapies best tailored to the needs of patients.
Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
A concise overview of the clinical development, use and effectiveness of enzalutamide in the treatment of advanced prostate cancer is provided, translational research addressing enzalUTamide response vs resistance is described and novel potential treatment strategies in the enzyme-resistant setting are highlighted.
Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer
This review examines their current clinical use and discusses future directions, in particular combination regimens, to maximize their efficacy, delay emergence of resistance and improve patient outcomes.
The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer
A comprehensive appraisal of the expanding landscape of systemic therapies for advanced PC is provided from an expert perspective, with a focus on novel classification and diagnostic tools that have been paving the way for the development of precision medicine in PC.
Therapy of Advanced Prostate Cancer: Targeting the Androgen Receptor Axis in Earlier Lines of Treatment
The key clinical trials that led to FDA approval of ARAT in the mHSPC and nmCRPC settings are summarized and potential limitations, future directions, and treatment-algorithms when selecting patients for early therapy are highlighted.
Non-metastatic castration-resistant prostate cancer: current status and future directions
The definition, diagnosis, treatment, and ongoing clinical trials in non-metastatic castration resistant prostate cancer (M0CRPC) are summarized and the role of newer imaging modalities in the detection of advanced prostate cancer is discussed.


ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer
ODM-201, a new-generation AR inhibitor with a unique molecular structure, is reviewed, in the treatment of CRPC, at a disease stage for which there is currently no approved treatment.
Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials
Results of the STAMPEDE trial in men with high-risk locally advanced or metastatic prostate cancer initiating long-term hormone therapy show that docetaxel in addition to ADT should be considered SOC for men with newly diagnosed mHSPC.
Enzalutamide in metastatic prostate cancer before chemotherapy.
Enzalutamide significantly decreased the risk of radiographic progression and death and delayed the initiation of chemotherapy in men with metastatic prostate cancer.
Abiraterone and increased survival in metastatic prostate cancer.
The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy.
Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer
It is concluded that the success of PCa therapies in the future depends on targeting molecular mechanisms underlying tumor recurrence that still may affect AR at pre-receptor, receptor, and post-rereceptor levels.
ARAMIS trial: Efficacy and safety of ODM-201 in men with high-risk nonmetastatic castration-resistant prostate cancer.
The ARAMIS trial will evaluate the efficacy and safety of ODM-201 in high-risk nmCRPC pts, a novel second-generation oral androgen receptor inhibitor that has demonstrated a tolerable safety profile and antineoplastic activity in progressive CRPC.
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
BACKGROUND The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-binding domain, which is the target of enzalutamide and abiraterone, but remains constitutively active as a
Androgen receptor targeting drugs in castration‐resistant prostate cancer and mechanisms of resistance
Promising therapies and novel biomarkers, such as AR‐V7, may lead to improved outcomes for CRPC patients and several novel agents may overcome resistance mechanisms.